Optical imaging agent developer Edinburgh Molecular Imaging (EM Imaging) has landed 3.1 million pounds (3.7 million euros) in financing to advance its molecular targeted systemic radiotherapy agents.
The Scottish company has developed the EMT-100 and EMT-101 therapeutic agents from its clinical stage imaging agent EMI-137, and it hopes to fast-track the new agents for radiotherapy treatments.
EMT-100 and EMT-101 feature peptides that target c-Met, which is overexpressed by many tumors compared to healthy tissue. The ultimate goal is to have the agents target several solid tumors and provide new treatment options for difficult-to-treat cancers, according to the company.
